The tumor cytosol miRNAs, fluid miRNAs and exosome miRNAs in lung cancer

Xin Qin, Haisheng Xu, Wenrong Gong, Wenbin Deng

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The focus of this review is to provide an update on the progress of microRNAs (miRNAs) as potential biomarkers for lung cancer. miRNAs are single-stranded, small noncoding RNAs that regulate gene expression and show tissue-specific signatures. Accumulating evidence indicates that miRNA expression patterns represent the in vivo status in physiology and disease. Moreover, miRNAs are stable in serum and other clinically convenient and available tissue sources, so they are being developed as biomarkers for cancer and other diseases. Cancer is currently the primary driver of the field, but miRNA biomarkers are being developed for many other diseases such as cardiovascular and central nervous system diseases. Here we examine the framework and scope of the miRNA landscape as it specifically relates to the translation of miRNA expression patterns/signatures into biomarkers for developing diagnostics for lung cancer. We focus on examining tumor cytosol miRNAs, fluid miRNAs, and exosome miRNAs in lung cancer, the connections among these miRNAs, and the potential of miRNA biomarkers for the development of diagnostics. In lung cancer, miRNAs have been studied in both cell populations and in the circulation. However, a major challenge is to develop biomarkers to monitor cancer development and to identify circulating miRNAs that are linked to cancer stage. Importantly, the fact that miRNAs can be successfully harvested from biological fluids allows for the development of biofluid biopsies, in which miRNAs as circulating biomarkers can be captured and analyzed ex vivo. Our hope is that these minimally invasive entities provide a window to the in vivo milieu of the patients without the need for costly, complex invasive procedures, rapidly moving miRNAs from research to the clinic.

Original languageEnglish (US)
Article number357
JournalFrontiers in Oncology
Volume4
Issue numberNOV
DOIs
StatePublished - 2014

Fingerprint

Exosomes
MicroRNAs
Cytosol
Lung Neoplasms
Neoplasms
Biomarkers
Small Untranslated RNA

Keywords

  • Biomarker
  • Lung cancer
  • microRNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The tumor cytosol miRNAs, fluid miRNAs and exosome miRNAs in lung cancer. / Qin, Xin; Xu, Haisheng; Gong, Wenrong; Deng, Wenbin.

In: Frontiers in Oncology, Vol. 4, No. NOV, 357, 2014.

Research output: Contribution to journalArticle

Qin, Xin ; Xu, Haisheng ; Gong, Wenrong ; Deng, Wenbin. / The tumor cytosol miRNAs, fluid miRNAs and exosome miRNAs in lung cancer. In: Frontiers in Oncology. 2014 ; Vol. 4, No. NOV.
@article{1aaa8edb9718427fadc53ba27b4f35a2,
title = "The tumor cytosol miRNAs, fluid miRNAs and exosome miRNAs in lung cancer",
abstract = "The focus of this review is to provide an update on the progress of microRNAs (miRNAs) as potential biomarkers for lung cancer. miRNAs are single-stranded, small noncoding RNAs that regulate gene expression and show tissue-specific signatures. Accumulating evidence indicates that miRNA expression patterns represent the in vivo status in physiology and disease. Moreover, miRNAs are stable in serum and other clinically convenient and available tissue sources, so they are being developed as biomarkers for cancer and other diseases. Cancer is currently the primary driver of the field, but miRNA biomarkers are being developed for many other diseases such as cardiovascular and central nervous system diseases. Here we examine the framework and scope of the miRNA landscape as it specifically relates to the translation of miRNA expression patterns/signatures into biomarkers for developing diagnostics for lung cancer. We focus on examining tumor cytosol miRNAs, fluid miRNAs, and exosome miRNAs in lung cancer, the connections among these miRNAs, and the potential of miRNA biomarkers for the development of diagnostics. In lung cancer, miRNAs have been studied in both cell populations and in the circulation. However, a major challenge is to develop biomarkers to monitor cancer development and to identify circulating miRNAs that are linked to cancer stage. Importantly, the fact that miRNAs can be successfully harvested from biological fluids allows for the development of biofluid biopsies, in which miRNAs as circulating biomarkers can be captured and analyzed ex vivo. Our hope is that these minimally invasive entities provide a window to the in vivo milieu of the patients without the need for costly, complex invasive procedures, rapidly moving miRNAs from research to the clinic.",
keywords = "Biomarker, Lung cancer, microRNA",
author = "Xin Qin and Haisheng Xu and Wenrong Gong and Wenbin Deng",
year = "2014",
doi = "10.3389/fonc.2014.00357",
language = "English (US)",
volume = "4",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "NOV",

}

TY - JOUR

T1 - The tumor cytosol miRNAs, fluid miRNAs and exosome miRNAs in lung cancer

AU - Qin, Xin

AU - Xu, Haisheng

AU - Gong, Wenrong

AU - Deng, Wenbin

PY - 2014

Y1 - 2014

N2 - The focus of this review is to provide an update on the progress of microRNAs (miRNAs) as potential biomarkers for lung cancer. miRNAs are single-stranded, small noncoding RNAs that regulate gene expression and show tissue-specific signatures. Accumulating evidence indicates that miRNA expression patterns represent the in vivo status in physiology and disease. Moreover, miRNAs are stable in serum and other clinically convenient and available tissue sources, so they are being developed as biomarkers for cancer and other diseases. Cancer is currently the primary driver of the field, but miRNA biomarkers are being developed for many other diseases such as cardiovascular and central nervous system diseases. Here we examine the framework and scope of the miRNA landscape as it specifically relates to the translation of miRNA expression patterns/signatures into biomarkers for developing diagnostics for lung cancer. We focus on examining tumor cytosol miRNAs, fluid miRNAs, and exosome miRNAs in lung cancer, the connections among these miRNAs, and the potential of miRNA biomarkers for the development of diagnostics. In lung cancer, miRNAs have been studied in both cell populations and in the circulation. However, a major challenge is to develop biomarkers to monitor cancer development and to identify circulating miRNAs that are linked to cancer stage. Importantly, the fact that miRNAs can be successfully harvested from biological fluids allows for the development of biofluid biopsies, in which miRNAs as circulating biomarkers can be captured and analyzed ex vivo. Our hope is that these minimally invasive entities provide a window to the in vivo milieu of the patients without the need for costly, complex invasive procedures, rapidly moving miRNAs from research to the clinic.

AB - The focus of this review is to provide an update on the progress of microRNAs (miRNAs) as potential biomarkers for lung cancer. miRNAs are single-stranded, small noncoding RNAs that regulate gene expression and show tissue-specific signatures. Accumulating evidence indicates that miRNA expression patterns represent the in vivo status in physiology and disease. Moreover, miRNAs are stable in serum and other clinically convenient and available tissue sources, so they are being developed as biomarkers for cancer and other diseases. Cancer is currently the primary driver of the field, but miRNA biomarkers are being developed for many other diseases such as cardiovascular and central nervous system diseases. Here we examine the framework and scope of the miRNA landscape as it specifically relates to the translation of miRNA expression patterns/signatures into biomarkers for developing diagnostics for lung cancer. We focus on examining tumor cytosol miRNAs, fluid miRNAs, and exosome miRNAs in lung cancer, the connections among these miRNAs, and the potential of miRNA biomarkers for the development of diagnostics. In lung cancer, miRNAs have been studied in both cell populations and in the circulation. However, a major challenge is to develop biomarkers to monitor cancer development and to identify circulating miRNAs that are linked to cancer stage. Importantly, the fact that miRNAs can be successfully harvested from biological fluids allows for the development of biofluid biopsies, in which miRNAs as circulating biomarkers can be captured and analyzed ex vivo. Our hope is that these minimally invasive entities provide a window to the in vivo milieu of the patients without the need for costly, complex invasive procedures, rapidly moving miRNAs from research to the clinic.

KW - Biomarker

KW - Lung cancer

KW - microRNA

UR - http://www.scopus.com/inward/record.url?scp=84915784783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915784783&partnerID=8YFLogxK

U2 - 10.3389/fonc.2014.00357

DO - 10.3389/fonc.2014.00357

M3 - Article

AN - SCOPUS:84915784783

VL - 4

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - NOV

M1 - 357

ER -